{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:01:47Z","timestamp":1787022107437,"version":"build-2736575974"},"reference-count":64,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["EY031758"],"award-info":[{"award-number":["EY031758"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007826","name":"American Glaucoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007048","name":"Mayo Foundation for Medical Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["EY21727"],"award-info":[{"award-number":["EY21727"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007048","name":"Mayo Foundation for Medical Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Glaucoma is the leading cause of irreversible blindness worldwide. Therapies for glaucoma are directed toward reducing intraocular pressure (IOP), the leading risk factor and only reliable therapeutic target via topical medications or with procedural intervention including laser or surgery. Though topical therapeutics are typically first line, less than 50% of patients take drops as prescribed. Sustained release technologies that decrease IOP for extended periods of time are being examined for clinical use. We recently identified Stanniocalcin-1, a naturally occurring hormone, as an IOP-lowering agent. Here, we show that a single injection into the anterior chamber of mice with an adeno-associated viral vector containing the transgene of stanniocalcin-1 results in diffuse and sustained expression of the protein and produces IOP reduction for up to 6 months. As the treatment effect begins to wane, IOP-lowering can be rescued with a repeat injection. Aqueous humor dynamic studies revealed an increase in outflow facility as the mechanism of action. This first-in-class therapeutic approach has the potential to improve care and reduce the rates of vision loss in the 80 million people worldwide currently affected by glaucoma.<\/jats:p>","DOI":"10.1371\/journal.pone.0269261","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T13:29:20Z","timestamp":1654003760000},"page":"e0269261","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8905-8588","authenticated-orcid":true,"given":"Gavin W.","family":"Roddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uttio","family":"Roy Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjersten J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8122-8215","authenticated-orcid":true,"given":"Tommy A.","family":"Rinkoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl R.","family":"Hann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-0221","authenticated-orcid":true,"given":"Vince A.","family":"Chiodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Clay","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9115-2485","authenticated-orcid":true,"given":"Michael P.","family":"Fautsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"issue":"3","key":"pone.0269261.ref001","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"HA Quigley","year":"2006","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"pone.0269261.ref002","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"YC Tham","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"pone.0269261.ref003","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.survophthal.2019.10.002","article-title":"How many aqueous humor outflow pathways are there?","volume":"65","author":"C Costagliola","year":"2020","journal-title":"Surv Ophthalmol."},{"issue":"6","key":"pone.0269261.ref004","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/aos.13790","article-title":"Initial intraocular pressure reduction by mono- versus multi-therapy in patients with open-angle glaucoma: results from the Glaucoma Intensive Treatment Study.","volume":"96","author":"C Linden","year":"2018","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"pone.0269261.ref005","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/13816810.2016.1164193","article-title":"Prostaglandins in the eye: Function, expression, and roles in glaucoma","volume":"38","author":"LP Doucette","year":"2017","journal-title":"Ophthalmic Genet"},{"issue":"Suppl1","key":"pone.0269261.ref006","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.survophthal.2008.08.010","article-title":"Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction","volume":"53","author":"CB Toris","year":"2008","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"pone.0269261.ref007","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1034\/j.1600-0420.1999.770612.x","article-title":"Latanoprost 0.005% and anterior segment uveitis","volume":"77","author":"SL Smith","year":"1999","journal-title":"Acta Ophthalmol Scand"},{"issue":"2","key":"pone.0269261.ref008","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0161-6420(98)92977-3","article-title":"Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients","volume":"105","author":"RE Warwar","year":"1998","journal-title":"Ophthalmology"},{"issue":"2","key":"pone.0269261.ref009","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/09273948.2017.1372485","article-title":"The Effect of Latanaprost on Intraocular Inflammation and Macular Edema.","volume":"27","author":"MR Razeghinejad","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"pone.0269261.ref010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/jcpt.12468","article-title":"Correlations of AFAP1, GMDS and PTGFR gene polymorphisms with intra-ocular pressure response to latanoprost in patients with primary open-angle glaucoma","volume":"42","author":"XJ Cui","year":"2017","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"pone.0269261.ref011","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3109\/02713683.2016.1143013","article-title":"PTGFR and SLCO2A1 Gene Polymorphisms Determine Intraocular Pressure Response to Latanoprost in Han Chinese Patients with Glaucoma","volume":"41","author":"P Zhang","year":"2016","journal-title":"Curr Eye Res"},{"issue":"5","key":"pone.0269261.ref012","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.ophtha.2014.12.038","article-title":"Association between SNPs of Metalloproteinases and Prostaglandin F2alpha Receptor Genes and Latanoprost Response in Open-Angle Glaucoma","volume":"122","author":"F Ussa","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"pone.0269261.ref013","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bjophthalmol-2013-304267","article-title":"Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension","volume":"98","author":"M Sakurai","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"pone.0269261.ref014","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ophtha.2007.03.025","article-title":"Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost","volume":"114","author":"M Sakurai","year":"2007","journal-title":"Ophthalmology"},{"issue":"1\u20132","key":"pone.0269261.ref015","first-page":"49","article-title":"A novel single nucleotide polymorphism, IVS2 -97A>T, in the prostaglandin F2alpha receptor gene was identified among the Malaysian patients with glaucoma","volume":"53","author":"HB Peng","year":"2007","journal-title":"Kobe J Med Sci"},{"issue":"2","key":"pone.0269261.ref016","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.joco.2017.09.002","article-title":"Compliance to topical anti-glaucoma medications among patients at a tertiary hospital in North India.","volume":"30","author":"K Rajurkar","year":"2018","journal-title":"J Curr Ophthalmol"},{"issue":"7","key":"pone.0269261.ref017","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","article-title":"The Most Common Barriers to Glaucoma Medication Adherence: A Cross-Sectional Survey","volume":"122","author":"PA Newman-Casey","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"pone.0269261.ref018","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ajo.2005.04.051","article-title":"Persistence and adherence with topical glaucoma therapy","volume":"140","author":"BL Nordstrom","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"pone.0269261.ref019","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1001\/jamaophthalmol.2014.3333","article-title":"Persistence of topical glaucoma medication: a nationwide population-based cohort study in Taiwan.","volume":"132","author":"DK Hwang","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"pone.0269261.ref020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/jcm5090079","article-title":"Adherence to Glaucoma Medications Over 12 Months in Two US Community Pharmacy Chains.","volume":"5","author":"M Feehan","year":"2016","journal-title":"J Clin Med."},{"issue":"1","key":"pone.0269261.ref021","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5301\/ejo.5000181","article-title":"Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension","volume":"23","author":"C Baudouin","year":"2012","journal-title":"Eur J Ophthalmol."},{"issue":"2","key":"pone.0269261.ref022","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/IJG.0000000000001713","article-title":"Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana","volume":"30","author":"E Kobia-Acquah","year":"2021","journal-title":"J Glaucoma"},{"issue":"3","key":"pone.0269261.ref023","doi-asserted-by":"crossref","first-page":"296","DOI":"10.5301\/ejo.5000220","article-title":"Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients","volume":"23","author":"GC Rossi","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"pone.0269261.ref024","doi-asserted-by":"crossref","first-page":"100901","DOI":"10.1016\/j.preteyeres.2020.100901","article-title":"Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma.","volume":"82","author":"UB Kompella","year":"2021","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"pone.0269261.ref025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/jovr.jovr_35_18","article-title":"Intraocular Pressure Fluctuation: Is It Important?","volume":"13","author":"JH Kim","year":"2018","journal-title":"J Ophthalmic Vis Res"},{"issue":"4","key":"pone.0269261.ref026","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.2353\/ajpath.2009.080476","article-title":"Anti-inflammatory and renal protective actions of stanniocalcin-1 in a model of anti-glomerular basement membrane glomerulonephritis","volume":"174","author":"L Huang","year":"2009","journal-title":"Am J Pathol"},{"issue":"2","key":"pone.0269261.ref027","doi-asserted-by":"crossref","first-page":"F248","DOI":"10.1152\/ajprenal.00260.2009","article-title":"Mammalian stanniocalcin-1 activates mitochondrial antioxidant pathways: new paradigms for regulation of macrophages and endothelium","volume":"298","author":"D. Sheikh-Hamad","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"pone.0269261.ref028","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/mt.2011.308","article-title":"Stanniocalcin-1 rescued photoreceptor degeneration in two rat models of inherited retinal degeneration","volume":"20","author":"GW Roddy","year":"2012","journal-title":"Mol Ther"},{"issue":"1","key":"pone.0269261.ref029","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/02713683.2019.1645184","article-title":"Stanniocalcin-1 is a Modifier of Oxygen-Induced Retinopathy Severity","volume":"45","author":"LA Dalvin","year":"2020","journal-title":"Curr Eye Res"},{"key":"pone.0269261.ref030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.freeradbiomed.2014.03.034","article-title":"Stanniocalcin-1 ameliorates lipopolysaccharide-induced pulmonary oxidative stress, inflammation, and apoptosis in mice","volume":"71","author":"SE Tang","year":"2014","journal-title":"Free Radic Biol Med"},{"issue":"18","key":"pone.0269261.ref031","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/onc.2009.65","article-title":"Stanniocalcin-1 acts in a negative feedback loop in the prosurvival ERK1\/2 signaling pathway during oxidative stress","volume":"28","author":"A Nguyen","year":"2009","journal-title":"Oncogene"},{"issue":"4","key":"pone.0269261.ref032","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.bbrc.2014.09.060","article-title":"Stanniocalcin-1 is induced by hypoxia inducible factor in rat alveolar epithelial cells","volume":"452","author":"Y Ito","year":"2014","journal-title":"Biochemical and biophysical research communications"},{"issue":"6","key":"pone.0269261.ref033","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/FJC.0000000000000146","article-title":"Recombinant adeno-associated virus-delivered hypoxia-inducible stanniocalcin-1 expression effectively inhibits hypoxia-induced cell apoptosis in cardiomyocytes","volume":"64","author":"X Shi","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"pone.0269261.ref034","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuroscience.2012.10.062","article-title":"Stanniocalcin 1 is important for poststroke functionality, but dispensable for ischemic tolerance","volume":"229","author":"A Durukan Tolvanen","year":"2013","journal-title":"Neuroscience"},{"issue":"23","key":"pone.0269261.ref035","doi-asserted-by":"crossref","first-page":"10604","DOI":"10.1128\/MCB.25.23.10604-10610.2005","article-title":"The murine stanniocalcin 1 gene is not essential for growth and development","volume":"25","author":"AC Chang","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"9","key":"pone.0269261.ref036","doi-asserted-by":"crossref","first-page":"e0138440","DOI":"10.1371\/journal.pone.0138440","article-title":"Severe Nephrotoxic Nephritis following Conditional and Kidney-Specific Knockdown of Stanniocalcin-1.","volume":"10","author":"L Huang","year":"2015","journal-title":"PLoS One."},{"issue":"10","key":"pone.0269261.ref037","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1681\/ASN.2013070690","article-title":"AKI after conditional and kidney-specific knockdown of stanniocalcin-1","volume":"25","author":"L Huang","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"pone.0269261.ref038","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1167\/iovs.16-21004","article-title":"Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure-Lowering Effects of Latanoprost","volume":"58","author":"GW Roddy","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"pone.0269261.ref039","doi-asserted-by":"crossref","first-page":"e0232591","DOI":"10.1371\/journal.pone.0232591","article-title":"Stanniocalcin-1 (STC-1), a downstream effector molecule in latanoprost signaling, acts independent of the FP receptor for intraocular pressure reduction.","volume":"15","author":"GW Roddy","year":"2020","journal-title":"PLoS One"},{"issue":"10","key":"pone.0269261.ref040","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1080\/02713683.2021.1899246","article-title":"Stanniocalcin-1 Reduced Intraocular Pressure in Two Models of Ocular Hypertension","volume":"46","author":"GW Roddy","year":"2021","journal-title":"Curr Eye Res"},{"issue":"6","key":"pone.0269261.ref041","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ymthe.2006.03.005","article-title":"Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection","volume":"13","author":"SG Jacobson","year":"2006","journal-title":"Mol Ther"},{"key":"pone.0269261.ref042","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.exer.2017.09.011","article-title":"Long-term photoreceptor rescue in two rodent models of retinitis pigmentosa by adeno-associated virus delivery of Stanniocalcin-1","volume":"165","author":"GW Roddy","year":"2017","journal-title":"Exp Eye Res"},{"issue":"2","key":"pone.0269261.ref043","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1167\/iovs.10-6069","article-title":"Assessment of aqueous humor dynamics in the mouse by a novel method of constant-flow infusion","volume":"52","author":"JC Millar","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"13","key":"pone.0269261.ref044","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1167\/iovs.17-22538","article-title":"Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents.","volume":"58","author":"U Roy Chowdhury","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"pone.0269261.ref045","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1167\/iovs.04-0338","article-title":"Effect of latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor","volume":"45","author":"JG Crowston","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"pone.0269261.ref046","doi-asserted-by":"crossref","first-page":"e0182473","DOI":"10.1371\/journal.pone.0182473","article-title":"Single stranded adeno-associated virus achieves efficient gene transfer to anterior segment in the mouse eye","volume":"12","author":"L Wang","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"pone.0269261.ref047","doi-asserted-by":"crossref","first-page":"e000398","DOI":"10.1136\/bmjophth-2019-000398","article-title":"Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review","volume":"4","author":"S Khanna","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"issue":"3","key":"pone.0269261.ref048","doi-asserted-by":"crossref","first-page":"E127","DOI":"10.1097\/BSD.0b013e3182a26553","article-title":"Effect of rAAV2-hTGFbeta1 Gene Transfer on Matrix Synthesis in an In Vivo Rabbit Disk Degeneration Model","volume":"29","author":"HF Liu","year":"2016","journal-title":"Clin Spine Surg"},{"issue":"3","key":"pone.0269261.ref049","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clinbiochem.2005.11.001","article-title":"Gene mapping for primary open angle glaucoma","volume":"39","author":"BJ Fan","year":"2006","journal-title":"Clin Biochem"},{"key":"pone.0269261.ref050","doi-asserted-by":"crossref","first-page":"108105","DOI":"10.1016\/j.exer.2020.108105","article-title":"Deconstructing aqueous humor outflow\u2014The last 50 years","volume":"197","author":"PL Kaufman","year":"2020","journal-title":"Exp Eye Res"},{"issue":"11","key":"pone.0269261.ref051","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/14728222.2017.1386174","article-title":"Open-angle glaucoma: therapeutically targeting the extracellular matrix of the conventional outflow pathway","volume":"21","author":"J O\u2019Callaghan","year":"2017","journal-title":"Expert Opin Ther Targets"},{"issue":"9","key":"pone.0269261.ref052","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3109\/02713683.2014.884593","article-title":"Prospects for lentiviral vector mediated prostaglandin F synthase gene delivery in monkey eyes in vivo","volume":"39","author":"ES Lee","year":"2014","journal-title":"Curr Eye Res"},{"issue":"8","key":"pone.0269261.ref053","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1167\/tvst.10.8.14","article-title":"Long-Term Decrease of Intraocular Pressure in Rats by Viral Delivery of miR-146a.","volume":"10","author":"C Luna","year":"2021","journal-title":"Transl Vis Sci Technol."},{"key":"pone.0269261.ref054","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.omtm.2019.06.009","article-title":"Transduction Pattern of AAVs in the Trabecular Meshwork and Anterior-Segment Structures in a Rat Model of Ocular Hypertension","volume":"14","author":"SH Lee","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"pone.0269261.ref055","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1167\/iovs.09-3847","article-title":"Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys.","volume":"51","author":"LK Buie","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"pone.0269261.ref056","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.ymthe.2017.03.008","article-title":"Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward","volume":"25","author":"J. Bennett","year":"2017","journal-title":"Mol Ther"},{"issue":"21","key":"pone.0269261.ref057","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber\u2019s congenital amaurosis","volume":"358","author":"JW Bainbridge","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0269261.ref058","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/jgm.886","article-title":"Mechanisms of AAV transduction in glaucoma-associated human trabecular meshwork cells","volume":"8","author":"T Borras","year":"2006","journal-title":"J Gene Med"},{"issue":"9","key":"pone.0269261.ref059","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/jez.a.313","article-title":"The stanniocalcin family of proteins","volume":"305","author":"GF Wagner","year":"2006","journal-title":"J Exp Zool A Comp Exp Biol"},{"issue":"9","key":"pone.0269261.ref060","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1167\/iovs.04-0366","article-title":"Long-term, targeted genetic modification of the aqueous humor outflow tract coupled with noninvasive imaging of gene expression in vivo","volume":"45","author":"N Loewen","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"pone.0269261.ref061","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.ophtha.2016.04.026","article-title":"Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study","volume":"123","author":"JD Brandt","year":"2016","journal-title":"Ophthalmology"},{"issue":"6","key":"pone.0269261.ref062","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40266-020-00769-8","article-title":"Bimatoprost Implant: First Approval.","volume":"37","author":"M. Shirley","year":"2020","journal-title":"Drugs Aging"},{"issue":"2","key":"pone.0269261.ref063","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40265-019-01248-0","article-title":"24-Month Phase I\/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients.","volume":"80","author":"ER Craven","year":"2020","journal-title":"Drugs"},{"issue":"12","key":"pone.0269261.ref064","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ophtha.2020.06.018","article-title":"Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).","volume":"127","author":"FA Medeiros","year":"2020","journal-title":"Ophthalmology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T13:30:33Z","timestamp":1654003833000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269261"}},"subtitle":[],"editor":[{"given":"Fan","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":64,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0269261","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]}}}